Investors Watch List: Emerald Oil, Inc. (NYSEMKT:EOX), Gilead Sciences Inc. (NASDAQ:GILD), Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB), Diamondback Energy, Inc. (NASDAQ:FANG), Calgon Carbon (NYSE:CCC)

Emerald Oil, Inc. (NYSEMKT:EOX) belongs to Basic Materials sector. Its weekly performance is -23.70%. On last trading day company shares ended up $3.09. Emerald Oil, Inc. (NYSEMKT:EOX) distance from 50-day simple moving average (SMA50) is -59.90%. Investment analysts at Canaccord Genuity set a $12.00 target price on shares of Emerald Oil (NYSEMKT:EOX)stock in a note issued to investors on Tuesday. The firm currently has a a “buy” rating on the stock. Canaccord Genuity’s target price suggests a potential upside of 121.81% from the stock’s previous close.

Gilead Sciences Inc. (NASDAQ:GILD) shares advanced 0.34% in last trading session and ended the day at $113.74. GILD Gross Margin is 86.00% and its return on assets is 42.70%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is 12.17%. On 1st July, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide (TAF) 25 mg with rilpivirine 25 mg (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older.

On 10 July, Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) shares remains unchanged and was closed at $1.66. NAVB EPS growth in last 5 year was 15.90%. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) year to date (YTD) performance is -12.17%. On 2 July, Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), announced that preclinical results in Kaposi’s Sarcoma (KS) demonstrated that a cytotoxic drug, doxorubicin, linked to Manocept™ was targeted to and dose-dependently taken up in CD206+ KS tumor cells and tumor associated macrophages (TAMs) and caused apoptotic death of the KS tumor cells and TAMs.

Diamondback Energy, Inc. (NASDAQ:FANG) ended the last trading day at $70.89. Company weekly volatility is calculated as 4.16% and price to cash ratio as 141.35. Diamondback Energy, Inc. (NASDAQ:FANG) showed a weekly performance of -3.06%. On July 7, 2015, Diamondback Energy, Inc. (NASDAQ:FANG) appointed Michael L. Hollis as the Company’s Vice President and Chief Operating Officer, effective July 1, 2015. Prior to this appointment, Mr. Hollis had served as the Company’s Vice President-Drilling since September 2011.

Calgon Carbon Corporation (NYSE:CCC) shares advanced 2.10% in last trading session and ended the day at $18.44. CCC Gross Margin is 35.30% and its return on assets is 8.30%. Calgon Carbon Corporation (NYSE:CCC) quarterly performance is -14.42%. On 30 June, Calgon Carbon Corporation (NYSE:CCC) has expressed its disappointment over the U.S. Supreme Court’s ruling that overturned the Environmental Protection Agency’s (“EPA”) MATS (Mercury and Air Toxics Standards) rule.

Leave a Reply

Your email address will not be published. Required fields are marked *